Barclays PLC Viridian Therapeutics, Inc.\De Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Barclays PLC holds 125,397 shares of VRDN stock, worth $2.32 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

125,397

Previous 125,397 -0.0%

Holding current value

$2.32 Million

Previous $2.85 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$12.16 - $23.33 $809,248 - $1.55 Million	66,550 Added 113.09%	125,397 $2.85 Million
Q2 2024 Aug 14, 2024	SELL	$11.6 - $17.26 $757,491 - $1.13 Million	-65,301 Reduced 52.6%	58,847 $765,000
Q1 2024 May 15, 2024	SELL	$17.09 - $23.82 $1.63 Million - $2.27 Million	-95,445 Reduced 43.46%	124,148 $2.17 Million
Q4 2023 Feb 15, 2024	BUY	$11.12 - $22.5 $978,960 - $1.98 Million	88,036 Added 66.92%	219,593 $4.78 Million
Q3 2023 Nov 07, 2023	SELL	$15.16 - $24.7 $1.91 Million - $3.11 Million	-125,979 Reduced 48.92%	131,557 $2.02 Million
Q2 2023 Aug 03, 2023	BUY	$22.57 - $29.67 $3.19 Million - $4.2 Million	141,393 Added 121.74%	257,536 $6.13 Million
Q1 2023 May 04, 2023	BUY	$25.04 - $37.6 $421,247 - $632,544	16,823 Added 16.94%	116,143 $2.95 Million
Q4 2022 Feb 13, 2023	SELL	$18.78 - $29.74 $10.4 Million - $16.5 Million	-554,431 Reduced 84.81%	99,320 $2.9 Million
Q3 2022 Nov 03, 2022	BUY	$10.7 - $25.5 $6.8 Million - $16.2 Million	635,456 Added 3473.39%	653,751 $13.4 Million
Q2 2022 Aug 12, 2022	BUY	$9.55 - $19.0 $12,367 - $24,605	1,295 Added 7.62%	18,295 $212,000
Q1 2022 May 16, 2022	BUY	$16.79 - $20.88 $285,430 - $354,960	17,000 New	17,000 $314,000

Others Institutions Holding VRDN

# of Institutions

180

Shares Held

76.7M

Call Options Held

581K

Put Options Held

439K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $739M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account